Conference Coverage For Competitive Intelligence Insights On Liquid Biopsy

Objective: Enabling Strategic Market Positioning in Liquid Biopsy Technology

A leading diagnostics company specializing in liquid biopsy tests sought expert support from DelveInsight to monitor and analyze competitor activity and data readouts at the European Society for Medical Oncology (ESMO) 2023 conference in Madrid, Spain - the premier oncology event in Europe. The client’s primary focus was on identifying the most promising liquid biopsy tests using key industry-specific keywords, particularly those with competitive sensitivity and specificity profiles. Specific attention was given to Multi-Cancer Early Detection (MCED) and Single Cancer Early Detection (SCED) tests relative to Minimal Residual Disease (MRD) assays within the liquid biopsy segment.

Challenge: Navigating a Rapidly Advancing and Diverse Liquid Biopsy Market

The liquid biopsy market is characterized by rapid technological innovation and intense competition, featuring a broad spectrum of test types and diagnostic applications. For the client to maintain a competitive edge, a nuanced and comprehensive understanding of emerging data and competitive testing methodologies showcased at ESMO was essential. Key difficulties included filtering high-priority abstracts related to MCED, SCED, and MRD, managing volume and complexity of scientific content, and synthesizing actionable intelligence in real-time during the conference.

Comprehensive Approach: End-to-End Conference Coverage and Competitive Intelligence

Pre-Conference Preparation

DelveInsight started by meticulously compiling a targeted conference planner and playbook tailored to the client’s objectives. This involved:

• Identifying and sorting potential abstracts aligned with client interests before the event began.
• Extracting relevant abstract titles and establishing priority levels to streamline focus.

Onsite and Virtual Conference Coverage

During ESMO 2023, the team provided robust real-time support including:

• Downloading and sharing high-resolution electronic posters (e-posters) of all high and medium priority presentations in PDF format.
• Delivering daily, detailed reports summarizing data readouts specifically for various high-priority liquid biopsy test types.
• Supplemental virtual analyst support to enhance coverage depth and provide swift analysis.

Post-Conference Analysis and Reporting

Post-event, DelveInsight delivered:

• Key takeaways documented from individual high-priority posters and oral presentations in clear, concise Word documents.
• Abstract-wise executive summaries of liquid biopsy test data, segmented by key companies for competitive benchmarking.
• Specialized executive summaries categorizing MCED, SCED, and MRD test results independently.
• Technology and analyte-wise breakdowns to highlight trends and innovations.
• Snippets and highlights of medium-priority abstracts enhancing content breadth.
• Insightful analysis on future prospects in the liquid biopsy field, guided by expert Key Opinion Leaders (KOLs).

Impact: Driving Informed Strategic Decisions and Competitive Edge

The comprehensive ESMO 2023 coverage focused on emerging liquid biopsy technologies empowered the client to:

• Monitor Competitive Activity: Gain early, actionable insights on top contenders and presentations from leading diagnostics companies, identifying breakthrough tests with superior accuracy metrics.
• Tailor R&D and Commercial Strategies: Adapt pipeline development, partnering, and marketing efforts based on benchmarked competitor data and evolving diagnostic trends in MCED and SCED.
• Enhance Stakeholder Communication: Provide internal teams and decision-makers with digestible, executive-level summaries and real-time updates to facilitate agile strategy adjustment.
• Anticipate Market Opportunities: Leverage detailed technology and analyte-specific reports to predict likely areas of growth and innovation, setting groundwork for future product launches.

The Future of Liquid Biopsy: Insights from ESMO Experts

Key Opinion Leaders (KOLs) emphasized the growing clinical utility of MCED and SCED approaches in early cancer detection, highlighting their transformative potential to shift paradigms toward non-invasive, broader-spectrum diagnostics. MRD testing continues to advance in precision, offering new avenues for minimal residual cancer detection and treatment personalization. Through detailed analysis of conference content and KOL perspectives, the client remains positioned on the forefront of this dynamic field.